Logo image
Back
Real-world 2-year treatment patterns among patients with psoriatic arthritis treated with injectable biologic therapies
Journal article   Open access   Peer reviewed

Real-world 2-year treatment patterns among patients with psoriatic arthritis treated with injectable biologic therapies

Jessica A. Walsh, Qian Cai, Iris Lin, Timothy Fitzgerald, Christopher D. Pericone and Soumya D. Chakravarty
Current medical research and opinion, v 36(7), pp 1245-1252
02 Jul 2020
DOI: https://doi.org/10.1080/03007995.2020.1754186
PMID: 32271088
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
https://doi.org/10.1080/03007995.2020.1754186View
Published, Version of Record (VoR)CC BY-NC-ND V4.0,  Open

Abstract

adjunctive medication usage biologic therapy persistence Psoriatic arthritis switching
Objectives: To assess long-term (2-year) biologic treatment patterns of psoriatic arthritis (PsA) patients who initiated adalimumab, certolizumab pegol, etanercept, golimumab, or ustekinumab. Methods: Adult patients with ≥1 pharmacy or medical claim for injectable PsA biologics (index date) were identified from the Optum's Clinformatics Data Mart (1 January 2013-31 December 2016). Adherence, persistence, post-discontinuation treatment patterns, and addition of adjunctive medications were evaluated by index biologic. Results: Of 996 patients included (mean [SD] age: 51.5 [12.6] years; female: 49.4%), the most common index biologics initiated were adalimumab (47.9%) and etanercept (34.5%). The mean [SD] proportion of days covered was 0.48 [0.32] for the index biologics. During the 24-month follow-up period, 19.7% of patients persisted on their index biologic; ustekinumab had the highest persistence rate (27.2%), followed by adalimumab (22.0%), golimumab (18.4%), certolizumab pegol (15.6%), and etanercept (15.4%). Of the 800 patients (80.3%) who discontinued their index biologic therapy, 35.0% restarted, 40.1% switched to another biologic, and 31.8% did neither during the follow-up period. The most common biologics patients switched to were adalimumab (31.2%) and ustekinumab (18.7%). Among patients who persisted with their index biologic for ≥90 days (n = 753), ≥1 adjunctive medication was added for 50.1% of patients. The most common adjunctive medications included corticosteroids (28.0% of patients), opioids (17.0%), nonsteroidal anti-inflammatory drugs (NSAIDs) (13.8%), and conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) (7.3%). Conclusions: In this real-world study of use of biologic PsA therapies, 24-month persistence was low (19.7%), and treatment was frequently supplemented with adjunctive medications.

Metrics

7 Record Views
16 citations in Web of Science
15 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Industry collaboration
Domestic collaboration
Web of Science research areas
Medicine, Research & Experimental
Logo image